Filing Details
- Accession Number:
- 0001209191-18-059447
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-11-20 16:45:44
- Reporting Period:
- 2018-11-16
- Accepted Time:
- 2018-11-20 16:45:44
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1131324 | Genomic Health Inc | GHDX | Services-Medical Laboratories (8071) | 770552594 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1333482 | J Kimberly Popovits | 301 Penobscot Dr. Redwood City CA 94063 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2018-08-29 | 1,860 | $0.00 | 57,657 | No | 5 | G | Direct | |
Common Stock | Disposition | 2018-11-16 | 5,855 | $76.31 | 171,127 | No | 4 | S | Indirect | Held by the Popovits 2010 Trust |
Common Stock | Disposition | 2018-11-16 | 3,199 | $77.11 | 167,928 | No | 4 | S | Indirect | Held by the Popovits 2010 Trust |
Common Stock | Disposition | 2018-11-16 | 946 | $77.93 | 166,982 | No | 4 | S | Indirect | Held by the Popovits 2010 Trust |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 5 | G | Direct | |
No | 4 | S | Indirect | Held by the Popovits 2010 Trust |
No | 4 | S | Indirect | Held by the Popovits 2010 Trust |
No | 4 | S | Indirect | Held by the Popovits 2010 Trust |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 12,298 | Indirect | Held by Morgan Stanley as Custodian for Benefit of Kimberly Popovits |
Footnotes
- Includes an aggregate of 51,204 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 14, 2018.
- Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- Represents weighted average sale price. Actual sale prices ranged from $75.61 to $76.59.
- Represents weighted average sale price. Actual sale prices ranged from $76.61 to $77.58.
- Represents weighted average sale price. Actual sale prices ranged from $77.61 to $78.21.